Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in PLoS One Retrieve available abstracts of 102 articles: HTML format

Single Articles

January 2025
1. ERICKSON A, Figiel S, Rajakumar T, Rao S, et al
   Clonal phylogenies inferred from bulk, single cell, and spatial transcriptomic analysis of epithelial cancers.
   PLoS One. 2025;20:e0316475.
   PubMed     Abstract available
   
   
   
2. SAWAYA M, Cordina-Duverger E, Lamy PJ, Tretarre B, et al
   Kidney and gallbladder stones and the risk of prostate cancer: Results from the EPICAP study.
   PLoS One. 2025;20:e0317760.
   PubMed     Abstract available
   
   
   
3. ANOSOVA O, Head A, Collins B, Alexiou A, et al
   Estimating the burden of underdiagnosis within England: A modelling study of linked primary care data.
   PLoS One. 2025;20:e0313877.
   PubMed     Abstract available
   
   
   
4. XU W, Zhu G, Wang X, Yan X, et al
   Predicting the risk of bone metastases in patients with newly diagnosed prostate cancer - Development and validation of a nomogram model.
   PLoS One. 2025;20:e0318051.
   PubMed     Abstract available
   
   
   
5. STAFFURTH JN, Sivell S, Baddeley E, Ahmedzai S, et al
   The impact of specialised gastroenterology services for pelvic radiation disease (PRD): Results from the prospective multi-centre EAGLE study.
   PLoS One. 2025;20:e0303356.
   PubMed     Abstract available
   
   
   
6. WILHELM ED, Dankert JT, Wiesehofer M, Wach S, et al
   xCT as a potential marker for neuroendocrine cells in high-risk prostate cancer and the relation to AL122023.1-miR-26a/30d/30e axis.
   PLoS One. 2025;20:e0318213.
   PubMed     Abstract available
   
   
   
7. CEN Y, Feng S, Xu Y, Zhang C, et al
   miR-455-3p has superior diagnostic potential to PSA in peripheral blood for prostate cancer.
   PLoS One. 2025;20:e0317385.
   PubMed     Abstract available
   
   
   
8. BELTRAN A, Parker L, Moral-Perez I, Caballero-Romeu JP, et al
   Impact of patients' age and comorbidities on prostate cancer overdiagnosis in clinical practice.
   PLoS One. 2025;20:e0315979.
   PubMed     Abstract available
   
   
   
9. SAYERS I, Joao Carvalho S, Davidson J, Elster N, et al
   A retrospective cohort study assessing medication coverage in patients with prostate cancer prescribed luteinizing hormone releasing hormone (LHRH) agonists in England.
   PLoS One. 2025;20:e0315208.
   PubMed     Abstract available
   
   
   
10. DAS G, Ptacek J, Campbell J, Li X, et al
    Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen.
    PLoS One. 2025;20:e0307353.
    PubMed     Abstract available
    
    
    
11. 
    Retraction: Targeted non AR mediated smart delivery of abiraterone to the prostate cancer.
    PLoS One. 2025;20:e0321800.
    PubMed    
    
    
    
12. ZHANGHUANG C, Wang H, Wang J, Li L, et al
    Chemotherapy and Heart-Specific Mortality in Elderly Men with Prostate Cancer: A Propensity Score Matching Analysis.
    PLoS One. 2025;20:e0318429.
    PubMed     Abstract available
    
    
    
13. LIU PC, Lin YS, Ou YC, Hsu CY, et al
    Comprehensive analysis of prostate cancer life expectancy, loss of life expectancy, and healthcare expenditures: Taiwan national cohort study spanning 2008 to 2019.
    PLoS One. 2025;20:e0310613.
    PubMed     Abstract available
    
    
    
14. ZHANG P, Chen T, Yang M
    Clinical feature and gene expression analysis in low prostate-specific antigen, high-grade prostate cancer.
    PLoS One. 2025;20:e0321728.
    PubMed     Abstract available
    
    
    
15. HELLSTERN M, Martinez C, Wallenhorst C, Beyersdorff D, et al
    Correction: Optimal length and temporal resolution of dynamic contrast-enhanced MR imaging for the differentiation between prostate cancer and normal peripheral zone tissue.
    PLoS One. 2025;20:e0322895.
    PubMed     Abstract available
    
    
    
16. JARBUR E, Godtman RA, Bonander C, Stromberg U, et al
    Associations between neighbourhood characteristics and participation in a population-based organised prostate cancer testing (OPT) programme: A register-based study of 50-year-old men.
    PLoS One. 2025;20:e0322643.
    PubMed     Abstract available
    
    
    
17. GUO P, Xing X, Wu K, Wang Y, et al
    1H-MRS study of hippocampus in advanced prostate cancer patients: Relationship between hippocampal secondary damage and cognitive disorder following combined androgen blockade therapy.
    PLoS One. 2025;20:e0323323.
    PubMed     Abstract available
    
    
    
18. ZHOU H, Xie M, Shi H, Shou C, et al
    Integrating multimodal imaging and peritumoral features for enhanced prostate cancer diagnosis: A machine learning approach.
    PLoS One. 2025;20:e0323752.
    PubMed     Abstract available
    
    
    
19. KHOSROWZADEH N, Saini AS, Samimi K, Chambers K, et al
    Disparities in physician compensation for breast and prostate cancer operations.
    PLoS One. 2025;20:e0323892.
    PubMed     Abstract available
    
    
    
20. PHILIBERT R, Beach SRH, Mills JA, Dawes K, et al
    Epigenetic assessments of alcohol consumption predict mortality in smokers at risk for lung cancer in the prostate, lung, colorectal and ovarian cancer screening trial.
    PLoS One. 2025;20:e0322783.
    PubMed     Abstract available
    
    
    
21. DANIELS J, Kyei KA, Frimpong-Boateng PD, Nyantakyi AY, et al
    Sexual function outcomes in prostate and cervical cancer patients treated with radiotherapy in sub-Saharan Africa: A cross-sectional study.
    PLoS One. 2025;20:e0324662.
    PubMed     Abstract available
    
    
    
22. MENBARI OSKOUIE I, Khatami F, Shiralizadeh Dezfuli A, Mashhadi R, et al
    Reducing the effective dosage of flutamide on prostate cancer cell lines through combination with selenium nanoparticles: An in-vitro study.
    PLoS One. 2025;20:e0318483.
    PubMed     Abstract available
    
    
    
23. OBENG F, Okai JNA, Sutherland E
    Predicting prostate cancer metastasis in Ghana: Comparison of multiparametric and PSA models.
    PLoS One. 2025;20:e0323180.
    PubMed     Abstract available
    
    
    
24. 
    Retraction: Evidence for a Pro-proliferative Feedback Loop in Prostate Cancer: The role of Epac1 and COX-2-dependent Pathways.
    PLoS One. 2025;20:e0325680.
    PubMed    
    
    
    
25. 
    Retraction: Receptor-Recognized alpha2-Macroglobulin Binds to Cell Surface-Associated GRP78 and Activates mTORC1 and mTORC2 Signaling in Prostate Cancer Cells.
    PLoS One. 2025;20:e0325675.
    PubMed    
    
    
    
26. ROTTEVEEL A, Lee WY, Kountouri Z, Stefanou N, et al
    Towards robust medical machine olfaction: Debiasing GC-MS data enhances prostate cancer diagnosis from urine volatiles.
    PLoS One. 2025;20:e0314742.
    PubMed     Abstract available
    
    
    
27. HOUSTEN AJ, Chang SH, Rice HE, L'Hotta AJ, et al
    Costs of non-metastatic prostate cancer treatment among privately insured men in the United States.
    PLoS One. 2025;20:e0324902.
    PubMed     Abstract available
    
    
    
28. LIU J, Liu X, Zeng H, Tong Y, et al
    Severe cutaneous adverse reactions associated with second-generation androgen receptor antagonists in prostate cancer patients.
    PLoS One. 2025;20:e0325448.
    PubMed     Abstract available
    
    
    
29. DI PAOLA FJ, Cardoso LH, Nikitopoulou E, Kulik B, et al
    Impact of mtG3PDH inhibitors on proliferation and metabolism of androgen receptor-negative prostate cancer cells: Role of extracellular pyruvate.
    PLoS One. 2025;20:e0325509.
    PubMed     Abstract available
    
    
    
30. ZHANG X, Wang Y
    Survival benefit of radical prostatectomy in bone metastatic prostate cancer stratified by disease characteristics: A SEER-based retrospective analysis.
    PLoS One. 2025;20:e0326429.
    PubMed     Abstract available
    
    
    
31. ADOTEY G, Alolga RN, Quarcoo A, Gedel MA, et al
    Cytotoxic activity of Ganoderma weberianum-sichuanese isolated from the Lower Volta River Basin of Ghana against human prostate carcinoma (PC-3), leukemic T cell (Jurkat), and plasmacytoid dendritic cell (pDC)-derived acute leukemia (PMDC05) cell line
    PLoS One. 2025;20:e0327087.
    PubMed     Abstract available
    
    
    
32. KLDIASHVILI E, Abiatari I, Kekelia E, Iordanishvili S, et al
    SOX2, PIWI proteins, and MALAT1 - plasma-based emerging biomarkers for cancer detection and monitoring.
    PLoS One. 2025;20:e0328557.
    PubMed     Abstract available
    
    
    
33. IBEGGAZENE S, Reale S, Scope A, Price G, et al
    Process evaluation for the STAMINA randomised controlled trial: A protocol.
    PLoS One. 2025;20:e0323275.
    PubMed     Abstract available
    
    
    
34. HAMADA M, Nakata E, Nakahara R, Sugihara S, et al
    Risk stratification for the prediction of skeletal-related events in patients with castration-resistant prostate cancer with bone metastases.
    PLoS One. 2025;20:e0328792.
    PubMed     Abstract available
    
    
    
35. PSZCZOLKOWSKA-KEPA B, Olejarz W, Gluszko A, Walpuski G, et al
    Exosome-mediated modulation of radioresistance: The radiation-induced bystander effect in prostate cancer cells.
    PLoS One. 2025;20:e0330501.
    PubMed     Abstract available
    
    
    
36. LI J, Dai X, Li P
    Research on prostate brachytherapy puncture control strategy based on adaptive PID control with FBG sensors.
    PLoS One. 2025;20:e0329065.
    PubMed     Abstract available
    
    
    
37. BACH CA, Hossain MN, Chaudhari IJ, Verrillo CE, et al
    A novel sialylation pathway mediated by extracellular vesicles in aggressive prostate cancer.
    PLoS One. 2025;20:e0329014.
    PubMed     Abstract available
    
    
    
38. WANG W, Xie G, Wu Z
    Development of a prostate cancer biochemical recurrence risk signature using machine learning and motor protein-related genes.
    PLoS One. 2025;20:e0332747.
    PubMed     Abstract available
    
    
    
39. DAMKLIANG K, Thongsuksai P, Wongsirichot T, Kayasut K, et al
    Detection and score grading for prostate adenocarcinoma using semantic segmentation.
    PLoS One. 2025;20:e0331613.
    PubMed     Abstract available
    
    
    
40. HWANG J, Kang BH, Park Y, Choi DH, et al
    Improving segmentation precision in prostate cancer adaptive radiation therapy with a patient-specific network.
    PLoS One. 2025;20:e0332603.
    PubMed     Abstract available
    
    
    January 2024
41. 
    Retraction: Potent Anti-Proliferative, Pro-Apoptotic Activity of the Maytenus Royleanus Extract against Prostate Cancer Cells: Evidence in In-Vitro and In-Vivo Models.
    PLoS One. 2024;19:e0297383.
    PubMed    
    
    
    
42. WESTERBERG M, Irenaeus S, Garmo H, Stattin P, et al
    Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: Nationwide, population-based register study.
    PLoS One. 2024;19:e0296804.
    PubMed     Abstract available
    
    
    
43. WU H, Wu Y, He P, Liang J, et al
    A meta-analysis for the diagnostic accuracy of SelectMDx in prostate cancer.
    PLoS One. 2024;19:e0285745.
    PubMed     Abstract available
    
    
    
44. JONEUS P, Johansson P, Langenskiold S
    Novel hormonal therapy versus standard of care-A registry-based comparative effectiveness evaluation for mCRPC-patients.
    PLoS One. 2024;19:e0290833.
    PubMed     Abstract available
    
    
    
45. NORIEGA LANDA E, Quaye GE, Su X, Badmos S, et al
    Urinary fatty acid biomarkers for prostate cancer detection.
    PLoS One. 2024;19:e0297615.
    PubMed     Abstract available
    
    
    
46. ZAFEIROPOULOU K, Kalampounias G, Alexis S, Anastasopoulos D, et al
    Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer.
    PLoS One. 2024;19:e0289904.
    PubMed     Abstract available
    
    
    
47. 
    Retraction: Somatostatin Derivative (smsDX) Targets Cellular Metabolism in Prostate Cancer Cells after Androgen Deprivation Therapy.
    PLoS One. 2024;19:e0299822.
    PubMed    
    
    
    
48. TAKAKUSAGI Y, Koge H, Kano K, Shima S, et al
    Five-year clinical outcomes of scanning carbon-ion radiotherapy for prostate cancer.
    PLoS One. 2024;19:e0290617.
    PubMed     Abstract available
    
    
    
49. DARBA J, Ascanio M
    Prostate cancer in Spain: A retrospective database analysis of hospital incidence and the direct medical costs.
    PLoS One. 2024;19:e0298764.
    PubMed     Abstract available
    
    
    
50. SHAHROKHI NEJAD S, Golzari Z, Zangiabadian M, Salehi Amniyeh Khozani AA, et al
    The association between zinc and prostate cancer development: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0299398.
    PubMed     Abstract available
    
    
    
51. PINKEOVA A, Tomikova A, Bertokova A, Fabinyova E, et al
    Glycoprofiling of proteins as prostate cancer biomarkers: A multinational population study.
    PLoS One. 2024;19:e0300430.
    PubMed     Abstract available
    
    
    
52. CHEN LC, Yang HJ, Yu BH, Lee MS, et al
    Association of spironolactone use with risk of urinary tract cancer in the general population: A matched population-based cohort study.
    PLoS One. 2024;19:e0300391.
    PubMed     Abstract available
    
    
    
53. FONSECA-ALVES CE, Leis-Filho AF, Lacerda ZA, de Faria Lainetti P, et al
    Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
    PLoS One. 2024;19:e0297043.
    PubMed     Abstract available
    
    
    
54. WU C, Zhu H, Zhang Y, Ding L, et al
    Interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer.
    PLoS One. 2024;19:e0290753.
    PubMed     Abstract available
    
    
    
55. RAJANALA SH, Ghale R, Nandakumar S, Chadalavada K, et al
    Quantifying Y chromosome loss in primary and metastatic prostate cancer by chromosome painting.
    PLoS One. 2024;19:e0301989.
    PubMed     Abstract available
    
    
    
56. KADRY MO, Abdel-Megeed RM
    CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.
    PLoS One. 2024;19:e0302264.
    PubMed     Abstract available
    
    
    
57. AZUR RAG, Olarte KCV, Ybanez WS, Ocampo AMM, et al
    CYB561 supports the neuroendocrine phenotype in castration-resistant prostate cancer.
    PLoS One. 2024;19:e0300413.
    PubMed     Abstract available
    
    
    
58. PARKER LA, Caballero-Romeu JP, Chilet-Rosell E, Hernandez-Aguado I, et al
    Knowledge and practices regarding prostate cancer screening in Spanish men: The importance of personal and clinical characteristics (PROSHADE study).
    PLoS One. 2024;19:e0303203.
    PubMed     Abstract available
    
    
    
59. YAMADA Y, Urabe F, Kimura S, Iwatani K, et al
    The prognostic significance of additional localized treatment to primary lesion in patients undergoing hormone therapy for metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0304963.
    PubMed     Abstract available
    
    
    
60. BUTT MA, Kaleem MF, Bilal M, Hanif MS, et al
    Using multi-label ensemble CNN classifiers to mitigate labelling inconsistencies in patch-level Gleason grading.
    PLoS One. 2024;19:e0304847.
    PubMed     Abstract available
    
    
    
61. BLOEMBERG J, Hoppener B, Coolen B, Sakes A, et al
    Design and evaluation of a pneumatic actuation unit for a wasp-inspired self-propelled needle.
    PLoS One. 2024;19:e0306411.
    PubMed     Abstract available
    
    
    
62. GUO H, Zhang L, Shao Y, An K, et al
    The impact of positive surgical margin parameters and pathological stage on biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0301653.
    PubMed     Abstract available
    
    
    
63. ROTH D, Safi M, Vilhelmsson Timmermand O, Sereti E, et al
    Evaluation of superficial xenograft volume estimation by ultrasound and caliper against MRI in a longitudinal pre-clinical radiotherapeutic setting.
    PLoS One. 2024;19:e0307558.
    PubMed     Abstract available
    
    
    
64. JEONG S, Cheon W, Kim S, Park W, et al
    Deep-learning-based segmentation using individual patient data on prostate cancer radiation therapy.
    PLoS One. 2024;19:e0308181.
    PubMed     Abstract available
    
    
    
65. HUANG PC, Huang LH, Yang CK, Li JR, et al
    Comparative analysis of novel hormonal agents in non-metastatic castration-resistant prostate cancer: A Taiwanese perspective.
    PLoS One. 2024;19:e0306900.
    PubMed     Abstract available
    
    
    
66. ALVAREZ-TOPETE E, Torres-Sanchez LE, Hernandez-Tobias EA, Veliz D, et al
    Circum-Mediterranean influence in the Y-chromosome lineages associated with prostate cancer in Mexican men: A Converso heritage founder effect?
    PLoS One. 2024;19:e0308092.
    PubMed     Abstract available
    
    
    
67. RAI B, Nordstrom T, Lantz A, Lund RL, et al
    Spatio-temporal variation in prostate cancer testing in Stockholm: A population-based study.
    PLoS One. 2024;19:e0308254.
    PubMed     Abstract available
    
    
    
68. SARAJI A, Wulf K, Stegmann-Frehse J, Kang D, et al
    Comprehensive transcriptomic analysis of prostate cancer lung metastases.
    PLoS One. 2024;19:e0306525.
    PubMed     Abstract available
    
    
    
69. LAI GS, Chen CS, Cheng JC, Li JR, et al
    Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients.
    PLoS One. 2024;19:e0309941.
    PubMed     Abstract available
    
    
    
70. WENNERBERG C, Ekstedt M, Schildmeijer K, Hellstrom A, et al
    Effects on patient activation of eHealth support in addition to standard care in patients after radical prostatectomy: Analysis of secondary outcome from a randomized controlled trial.
    PLoS One. 2024;19:e0308555.
    PubMed     Abstract available
    
    
    
71. SALVIOLI M, Vandelaer L, Baena E, Schneider K, et al
    The effect of tumor composition on the success of adaptive therapy: The case of metastatic Castrate-Resistant Prostate Cancer.
    PLoS One. 2024;19:e0308173.
    PubMed     Abstract available
    
    
    
72. O'DONNELL A, Cronin M, Moghaddam S, Wolsztynski E, et al
    Pre-operative prediction of BCR-free survival with mRNA variables in prostate cancer.
    PLoS One. 2024;19:e0311162.
    PubMed     Abstract available
    
    
    
73. MARSDEN T, Attard G, Punwani S, Giganti F, et al
    The RECONCILE study protocol: Exploiting image-based risk stratification in early prostate cancer to discriminate progressors from non-progressors (RECONCILE).
    PLoS One. 2024;19:e0295994.
    PubMed     Abstract available
    
    
    
74. KILERCIK M, Ozgur E, Sahin S, Sen Dogan B, et al
    Detection of circulating tumor cells in non-metastatic prostate cancer through integration of a microfluidic CTC enrichment system and multiparametric flow cytometry.
    PLoS One. 2024;19:e0312296.
    PubMed     Abstract available
    
    
    
75. SANCHEZ-FERNANDEZ D, Eguibar A, Lopez C, Cuesta AM, et al
    Effect of 5beta-dihydrotestosterone on vasodilator function and on cell proliferation.
    PLoS One. 2024;19:e0312080.
    PubMed     Abstract available
    
    
    
76. LI R, Chen X, Wang Y
    Adverse events analysis of Relugolix (Orgovyx(R)) for prostate cancer based on the FDA Adverse Event Reporting System (FAERS).
    PLoS One. 2024;19:e0312481.
    PubMed     Abstract available
    
    
    
77. WANG X, Jiang R, Shen J, Chen S, et al
    Transitions in metabolic syndrome and metabolic obesity status over time and risk of urologic cancer: A prospective cohort study.
    PLoS One. 2024;19:e0311492.
    PubMed     Abstract available
    
    
    
78. TANG Z, Li S, Zeng M, Zeng L, et al
    The association between systemic immune-inflammation index and prostate-specific antigen: Results from NHANES 2003-2010.
    PLoS One. 2024;19:e0313080.
    PubMed     Abstract available
    
    
    
79. PAPADOPOULOS E, Wong AKO, Law SHC, Zhang LZJ, et al
    Correction: The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer.
    PLoS One. 2024;19:e0314372.
    PubMed     Abstract available
    
    
    
80. 
    Retraction: Human Chorionic Gonadotropin beta Induces Migration and Invasion via Activating ERK1/2 and MMP-2 in Human Prostate Cancer DU145 Cells.
    PLoS One. 2024;19:e0314356.
    PubMed    
    
    
    
81. ANTON A, Hutchinson R, Hovens CM, Christie M, et al
    An immune suppressive tumor microenvironment in primary prostate cancer promotes tumor immune escape.
    PLoS One. 2024;19:e0301943.
    PubMed     Abstract available
    
    
    
82. MORIASI G, Ngugi M, Mwitari P, Omwenga G, et al
    Antioxidant, anti-prostate cancer potential, and phytochemical composition of the ethyl acetate stem bark extract of Boascia coriacea (Pax.).
    PLoS One. 2024;19:e0309258.
    PubMed     Abstract available
    
    
    
83. WEINSTEIN SJ, Parisi D, Mondul AM, Layne TM, et al
    Vitamin D binding protein genetic isoforms, serum vitamin D, and cancer risk in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    PLoS One. 2024;19:e0315252.
    PubMed     Abstract available
    
    
    
84. AZAM H, Veale C, Zitzmann K, Marcone S, et al
    Identification of druggable targets from the interactome of the Androgen Receptor and Serum Response Factor pathways in prostate cancer.
    PLoS One. 2024;19:e0309491.
    PubMed     Abstract available
    
    
    
85. ZHANG T, Li W, Wei H, Huang Z, et al
    Prognostic value of baseline alkaline phosphatase of 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0307826.
    PubMed     Abstract available
    
    
    
86. MAJUMDAR K, Silva R, Perry AS, Watson RW, et al
    A novel family of beta mixture models for the differential analysis of DNA methylation data: An application to prostate cancer.
    PLoS One. 2024;19:e0314014.
    PubMed     Abstract available
    
    
    
87. GRIFFIN MA, Culp WTN, Chohan AS, Johnson EG, et al
    Effect of glyceryl trinitrate and clevidipine administration on CT angiogram findings in dogs undergoing prostatic artery embolization for prostatic carcinoma.
    PLoS One. 2024;19:e0316080.
    PubMed     Abstract available
    
    
    
88. GUO Y, Wang S, Liu Q, Dong Y, et al
    St-N, a novel alkaline derivative of stevioside, reverses docetaxel resistance by targeting lysosomes in vitro and in vivo.
    PLoS One. 2024;19:e0316268.
    PubMed     Abstract available
    
    
    
89. CHRISTIE-DE JONG F, Eberhardt J, Ling J, Kotzur M, et al
    The PROCAN-B study protocol: Early diagnosis of PROstate CANcer for Black men-a community-centred participatory approach in Scotland and the North-East of England.
    PLoS One. 2024;19:e0315288.
    PubMed     Abstract available
    
    
    
90. RAMASWAMY A, Hung M, Pelt J, Iranmahboub P, et al
    Ascertaining provider-level implicit bias in electronic health records with rules-based natural language processing: A pilot study in the case of prostate cancer.
    PLoS One. 2024;19:e0314989.
    PubMed     Abstract available
    
    
    January 2023
91. NYATI S, Stricker H, Barton KN, Li P, et al
    A phase I clinical trial of oncolytic adenovirus mediated suicide and interleukin-12 gene therapy in patients with recurrent localized prostate adenocarcinoma.
    PLoS One. 2023;18:e0291315.
    PubMed     Abstract available
    
    
    
92. OKUMURA S, Ohsato Y
    A novel rapid detection method for a single-nucleotide substitution mutation derived from canine urothelial and prostatic carcinoma cells present in small amounts in urine sediments.
    PLoS One. 2023;18:e0286229.
    PubMed     Abstract available
    
    
    
93. LI J, Gu T, Hu S, Jin B, et al
    Anti-proliferative effect of Cannabidiol in Prostate cancer cell PC3 is mediated by apoptotic cell death, NFkappaB activation, increased oxidative stress, and lower reduced glutathione status.
    PLoS One. 2023;18:e0286758.
    PubMed     Abstract available
    
    
    
94. HILLOWE A, Gordon C, Wang L, Rizzo RC, et al
    Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells.
    PLoS One. 2023;18:e0292483.
    PubMed     Abstract available
    
    
    
95. LYLES RDZ, Martinez MJ, Sherman B, Schurer S, et al
    Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens.
    PLoS One. 2023;18:e0287126.
    PubMed     Abstract available
    
    
    
96. JOHANSSON P, Joneus P, Langenskiold S
    Causal inferences and real-world evidence: A comparative effectiveness evaluation of abiraterone acetate against enzalutamide.
    PLoS One. 2023;18:e0293000.
    PubMed     Abstract available
    
    
    
97. LUINING WI, Oprea-Lager DE, Vis AN, van Moorselaar RJA, et al
    Optimization and validation of 18F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer.
    PLoS One. 2023;18:e0293672.
    PubMed     Abstract available
    
    
    
98. CAMERON JK, Chandrasiri U, Millar J, Aitken JF, et al
    Disease mapping: Geographic differences in population rates of interventional treatment for prostate cancer in Australia.
    PLoS One. 2023;18:e0293954.
    PubMed     Abstract available
    
    
    
99. SIBERT NT, Kurth T, Breidenbach C, Wesselmann S, et al
    Prediction models of incontinence and sexual function one year after radical prostatectomy based on data from 20 164 prostate cancer patients.
    PLoS One. 2023;18:e0295179.
    PubMed     Abstract available
    
    
    
100. KWON SY, Park JM
     The assessment of erectile dysfunction after radical prostatectomy using pudendal somatosensory evoked potential.
     PLoS One. 2023;18:e0292847.
     PubMed     Abstract available
     
     
     
101. XIAO Z, Xiao P, Wang Y, Fang C, et al
     Risk of cancer in acromegaly patients: An updated meta-analysis and systematic review.
     PLoS One. 2023;18:e0285335.
     PubMed     Abstract available
     
     
     
102. CHANG HJ, Moi SH, Chan YJ, Lan TY, et al
     A non-socially-sensitive predictive model of prostate cancer for Asian males with benign prostatic hyperplasia: A multi-site cross-sectional case-control study.
     PLoS One. 2023;18:e0295608.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.